GetTopicDetailResponse(id=bafd3539de, topicName=Blueprint, introduction=Blueprint, content=null, image=null, comments=5, allHits=845, url=https://h5.medsci.cn/topic?id=3539, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=98669, tagList=[TagDto(tagId=98669, tagName=Blueprint)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1780392, encodeId=5f6a1e8039222, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, objectTitle=Agendia在ASCO 2021上呈報(bào)創(chuàng)新性FLEX研究的數(shù)據(jù)，展示MammaPrint和BluePrint對廣大類別患者群體的效用, objectType=article, longId=212564, objectId=6f2921256483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f2921256483, replyNumber=0, likeNumber=90, createdTime=2022-05-01, rootId=0, userName=1249883fm12暫無昵稱, userId=d4902500082, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f2921256483, moduleTitle=Agendia在ASCO 2021上呈報(bào)創(chuàng)新性FLEX研究的數(shù)據(jù)，展示MammaPrint和BluePrint對廣大類別患者群體的效用, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6f2921256483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1780390, encodeId=24c51e8039022, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, objectTitle=羅氏與Blueprint達(dá)成17億美元協(xié)議：合作開發(fā)RET抑制劑pralsetinib治療肺癌和甲狀腺癌, objectType=article, longId=197610, objectId=85f519e610f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85f519e610f2, replyNumber=0, likeNumber=91, createdTime=2021-04-10, rootId=0, userName=1249883fm12暫無昵稱, userId=d4902500082, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85f519e610f2, moduleTitle=羅氏與Blueprint達(dá)成17億美元協(xié)議：合作開發(fā)RET抑制劑pralsetinib治療肺癌和甲狀腺癌, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=85f519e610f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1780389, encodeId=c7551e8038984, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, objectTitle=Blueprint的Ayvakit成為美國獲批治療罕見胃腸道間質(zhì)瘤突變的靶向療法, objectType=article, longId=186045, objectId=eda21860459a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eda21860459a, replyNumber=0, likeNumber=88, createdTime=2020-01-16, rootId=0, userName=1249883fm12暫無昵稱, userId=d4902500082, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eda21860459a, moduleTitle=Blueprint的Ayvakit成為美國獲批治療罕見胃腸道間質(zhì)瘤突變的靶向療法, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=eda21860459a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1780391, encodeId=af5b1e8039176, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, objectTitle=吉利德Kite副總裁離職、拜耳CEO任期延長、BMS腫瘤研發(fā)首腦加入Blueprint……, objectType=article, longId=200934, objectId=8f8c200934f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8c200934f5, replyNumber=0, likeNumber=80, createdTime=2021-02-11, rootId=0, userName=1249883fm12暫無昵稱, userId=d4902500082, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8c200934f5, moduleTitle=吉利德Kite副總裁離職、拜耳CEO任期延長、BMS腫瘤研發(fā)首腦加入Blueprint……, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8f8c200934f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1780388, encodeId=436a1e8038852, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, objectTitle=基石藥業(yè)合作伙伴Blueprint Medicines公布EXPLORER試驗(yàn)新近進(jìn)展, objectType=article, longId=155888, objectId=52071558881f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52071558881f, replyNumber=0, likeNumber=67, createdTime=2019-05-03, rootId=0, userName=1249883fm12暫無昵稱, userId=d4902500082, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52071558881f, moduleTitle=基石藥業(yè)合作伙伴Blueprint Medicines公布EXPLORER試驗(yàn)新近進(jìn)展, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=52071558881f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
